Document is current
Any future updates will be listed below
-
Authors
Waury, Katharina http://orcid.org/0000-0002-8570-7640
Willemse, Eline A. J. http://orcid.org/0000-0001-9140-4243
Vanmechelen, Eugeen http://orcid.org/0000-0002-9466-5366
Zetterberg, Henrik http://orcid.org/0000-0003-3930-4354
Teunissen, Charlotte E. http://orcid.org/0000-0002-4061-0837
Abeln, Sanne http://orcid.org/0000-0002-2779-7174
-
Funding
Funding for this research was provided by:
European Union’s Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement (860197, 860197, 860197, 860197, 860197, 860197)
- License Information
-
More Information
Article History
Received: 19 June 2022
Accepted: 25 October 2022
First Online: 15 November 2022
Declarations
:
: Not applicable.
: Not applicable.
: EV is a co-founder of ADx NeuroSciences. HZ has served at scientific advisory boards and/or as a consultant for Abbvie, Alector, Eisai, Denali, Roche Diagnostics, Wave, Samumed, Siemens Healthineers, Pinteon Therapeutics, Nervgen, AZTherapies, CogRx, and Red Abbey Labs, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure and Biogen, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (all outside submitted work). CT has a collaboration contract with ADx Neurosciences, Quanterix and Eli Lilly, performed contract research or received grants from AC-Immune, Axon Neurosciences, Biogen, Brainstorm Therapeutics, Celgene, EIP Pharma, Eisai, PeopleBio, Roche, Toyama, Vivoryon, and has a speaker contract with Roche.The MIRIADE project includes the following commercial beneficiaries and partners: ADxNeuroscience, ENPICOM, LGC Limited, PeopleBio, Inc., Olink, Quanterix, and Roche.
